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Abstract
Currently, cancer therapy remains limited by a “one-size-fits-all” approach, whereby treatment decisions are based
mainly on the clinical stage of disease, yet fail to reference the individual’s underlying biology and its role driving
malignancy. Identifying better personalized therapies for cancer treatment is hindered by the lack of high-quality
“omics” data of sufficient size to produce meaningful results and the ability to integrate biomedical data from dis-
parate technologies. Resolving these issues will help translation of therapies from research to clinic by helping clini-
cians develop patient-specific treatments based on the unique signatures of patient’s tumor. Here we describe the
Georgetown Database of Cancer (G-DOC), a Web platform that enables basic and clinical research by integrating
patient characteristics and clinical outcome data with a variety of high-throughput research data in a unified environ-
ment. While several rich data repositories for high-dimensional research data exist in the public domain, most focus
on a single-data type and do not support integration across multiple technologies. Currently, G-DOC contains data
from more than 2500 breast cancer patients and 800 gastrointestinal cancer patients, G-DOC includes a broad
collection of bioinformatics and systems biology tools for analysis and visualization of four major “omics” types:
DNA, mRNA, microRNA, and metabolites. We believe that G-DOC will help facilitate systems medicine by provid-
ing identification of trends and patterns in integrated data sets and hence facilitate the use of better targeted
therapies for cancer. A set of representative usage scenarios is provided to highlight the technical capabilities of
this resource.
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Introduction
With the sequencing of the human genome and availability of high-
power computational methods and a variety of high-throughput “omics”
technologies (e.g., genomics, transcriptomics, and metabolomics), can-
cer research and care are poised to undergo a revolutionary change. These
new technologies and approaches have fueled the rise of systems biol-
ogy, which is now fully established as a discipline. The new and emerging
field of systems medicine, an application of systems biology approaches
to biomedical problems in the clinical setting, leverages complex compu-
tational tools and high-dimensional data to derive personalized assess-
ments of disease risk. Systems medicine offers the potential for more
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effective individualized diagnosis, prognosis, and treatment options.
Achieving this goal requires the effective use of petabytes of data, which
necessitates the development of both new types of tools and a new type of
physician—one with a grasp of modern computational sciences, “omics”
technologies, and a systems approach to the practice of medicine. As
part of this transformation, clinicians will need views of integrated bio-
medical data fromdisparate sources andwill begin to use validated in silico
methods for analysis. A critical factor in the success of systems medicine
will be the ease with which high-quality, high-dimensional data can be
integrated, redistributed, and analyzed both within and across functional
domains. This is enabled through effective application of translational
bioinformatics [1], which is defined as the development of storage, ana-
lytic, and interpretive methods to optimize the transformation of increas-
ingly voluminous biomedical data into proactive, predictive, preventative,
and participatory health, and helps link knowledge across biologic and
clinical realms [2].
To enable the practice of an integrative translational and systems-
based approach to research and medicine, we at the Lombardi Com-
prehensive Cancer Center, Georgetown University, have developed
a feature-rich, novel, and shareable research translational informatics
infrastructure to allow physician scientists and translational researchers
to mine and analyze a variety of “omics” data in the context of consis-
tently defined clinical outcomes data for cancer patients. By providing
a powerful but easy to use interface, Georgetown Database of Cancer
(G-DOC) was designed specifically to address the activation barrier for
use of biomedical informatics tools by basic, clinical, and translational
researchers. G-DOC contains a wide variety of analytic tools and capa-
bilities, including integrated viewers for genomic features and three-
dimensional drug-target complex structures. To help support effective
patient group comparisons, G-DOC supports flexible clinical criteria
browsing to enable selection of specific patient cohorts and facilitates
the generation of detailed reports and informative publication-quality
plots. Internal chemical compound libraries can be screened easily using
the integrated structure and detailed molecular property search func-
tions, with the goal of identifying new therapeutic candidate molecules.
G-DOC also allows researchers to securely share knowledge with others
through a powerful suite of collaboration-enabling features operating
within its secure environment.
The first public version of the G-DOCWeb portal was launched in
April 2011 for the Georgetown University research community and
their collaborators, providing cancer researchers with a broad range
of data reduction, visualization, and analysis tools and a large knowl-
edge base of published “omics” data sets from previously published
cancer clinical studies and a smaller set of private data sets. Currently
G-DOC includes data collected frommore than 2500 samples of breast
cancer and nearly 800 samples of gastrointestinal (GI) cancers (liver,
colon, stomach, and pancreas). Four types of “omics” data are sup-
ported: mRNA and microRNA (miRNA) expression, copy number
variation, and metabolite mass spectrometry data. All are linked to de-
identified patient clinical information, markedly increasing their value.
G-DOC also contains a manually curated database of small molecules
as potential drug candidates for key biomarkers/target proteins and a set
of curated cancer findings from integrated data sets and publications.
The G-DOC data repository is also designed to store multiple types
of metadata associated with individual samples and patients includ-
ing demographic data, clinical outcome, and tumor-specific phenotype
data that could be either quantitative or qualitative, and could be either
categorical or continuous. The data in G-DOC are uniformly processed
using validated algorithms within the R-based bioinformatics toolbox
(Bioconductor) [3], formatted and mapped using R scripts, and then
uploaded to the central database. The data and the analysis results
are shared within a G-DOC collaborative group, or a set of groups,
administered by the data provider to provide controlled access to data
and analysis.
Specific data analysis tools in the G-DOC environment include
differential expression analysis, heat maps and hierarchical clustering,
principal component analysis (PCA), survival analysis (Kaplan-Meier),
gene-disease, gene-compound, gene-protein interaction networks ren-
dered in the Cytoscape environment, and a growing collection of more
specialized tools such as a toolbox for copy number alteration (CNA)
data analysis. The latter suite of analyses includes chromosomal in-
stability (CIN) index calculations for DNA segments, cytobands, and
whole chromosomes based on data from CGH array and single nucleo-
tide polymorphism (SNP) array technologies. The results of omics data
analysis are mapped onto an integrated human genome browser at the
level of either the individual patients and/or cohorts of patients, each
defined by clinical attributes for ease of viewing and analysis. G-DOC
allows researchers to combine the commonly used clinical information-
personal history, physical examination, laboratory studies, radiology
studies, family history, and other pertinent data—with a detailed “omics”
analysis of the patient’s cancer to facilitate exploration of the clini-
cal and molecular factors that determine disease outcome. The results
section provides a detailed and demonstrative workflow of a prototypical
analysis of a breast carcinoma data set that highlights many of the value-
adding capabilities of the G-DOC resource, including cohort selection,
group comparison, PCA, and target exploration.
Key Features of G-DOC
G-DOC has easy-to-use search capabilities for clinical data, studies,
biospecimen, omics data, small molecules, and key published find-
ings. The G-DOC Web portal was designed to provide powerful bio-
informatics capabilities to users with a variety of backgrounds and skill
levels with computational tools. One of the most effective ways for a
new user to begin using G-DOC’s capabilities is through the “Quick
Start” page. The left-hand side of this page consists of a series of selec-
tion options, and it allows users to filter the data; thus, the user can
focus on only the most appropriate data sets for their needs. The
right-hand side of the page displays a graphical summary of the available
data that fits the specified criteria. An illustrative example can be seen
in Figure 1, which shows the number of breast cancer studies available
in the database that have data on recurrence; a tool-tip feature helps
display the various “omics” and clinical data elements available for each
of these studies. Data from patient cohorts can be further analyzed from
this page in a variety of ways using a right-click on the study name.
Cancer research findings can be searched by entering names of genes,
proteins, cancer type, investigators, or authors in the simple textbox
search on the G-DOC home page. Findings are not meant to be com-
prehensive or cover all known cancer biology but instead provide a
quick search and retrieval mechanism for key discoveries in the disease
areas of interest to investigators who provide data to G-DOC. It is
anticipated that this collection will be significantly expanded over time,
and may be augmented by other cancer summary data compilations.
G-DOC Systems Biology Analysis and Visualization
G-DOC supports compute-intensive, high-memory tasks such as
class comparison, hierarchical clustering, principal component analysis,
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and network analysis for transcriptomic, genomic, and metabolomic
data. Because these data sets could be as large as 4 GB, the development
of an analytic cluster to allow for several simultaneous analytic jobs was
needed to support community-level use of these services. Data in G-
DOC can also be easily used to perform advanced systems biology anal-
ysis of regulatory pathways and interaction networks of genes,
miRNAs, and metabolites that are both perturbed and most relevant
to the available phenotypic changes.
miRNA has recently emerged as a new and important class of cel-
lular regulators. There is strong evidence that aberrant expression of
miRNA is associated with a broad spectrum of human diseases includ-
ing cancer, diabetes, cardiovascular, and psychologic disorders [4–7].
The relatively small number of miRNAs discovered in humans to date
(∼1733 miRNAs, miRBase17.0 [8]) are involved in regulation of a
large number of human genes, perhaps as many 80% of known genes
[9]. miRNAs have exceptional potential as biomarkers because of their
relative abundance, highly specific expression, and stable presence in
serum and plasma [10]. In fact, circulating miRNAs are sensitive bio-
markers for colorectal cancer (CRC) detection and compare favorably
with the fecal occult blood test [11]. Circulating miRNAs in both urine
and serum hold tremendous potential as biomarkers for both early de-
tection of GI cancers and prognostic assessment. Processed miRNA
data (see Methods section) can be visualized using heat maps and
PCA plots to identify signatures that distinguish patient groups of in-
terest (e.g., cancer vs normal, relapse vs nonrelapse). As an example, Fig-
ure 2 shows miRNAs differentially expressed between colorectal cancer
and normal samples stored in G-DOC. A meta-analysis of differentially
expressed miRNAs from stage II, III, and IV CRC samples can be de-
rived using the Venn diagram feature and then exported for further
pathway analysis.
Metabolomics is a rapidly evolving field that aims to identify and
quantify the concentration changes of all the metabolites in a given bio-
fluid, or tissue extract, from a patient. The anticipated contribution of
metabolomics to the field of biomedical science is highlighted by its
presence in the current National Institutes of Health roadmap [12].
The application of metabolomics to understand the manifestation
and progression of complex diseases such as GI cancers represents a
powerful means to identify the earliest markers associated with attri-
butes such as recurrence and treatment response. G-DOC includes a
sophisticated data analysis pipeline (see Methods section) to enable
detection of potential prognostic and diagnostic molecular markers in
(noninvasive) serum and urine using metabolomics. Figure 3 shows a
PCA plot using 42 metabolite peaks that differentiate between recurrent
and nonrecurrent cases in a currently private G-DOC GI cancer cohort
(unpublished observations; public access to these data will be available
through G-DOC upon acceptance for publication). Individual samples,
Figure 1. G-DOC quick search showing the number of breast cancer studies available in the database patient annotations for neo-
plastic relapse.
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represented as points on the PCA plot, can be selected to view further
clinical details of that specific patient.
DNA copy number changes are common in cancers, often driving
underlying biology and affecting clinical outcomes. G-DOC provides
the genomic “map” of patient copy number profile and the significant
consensus regions derived from the CIN index. The utility of this novel
technique has been shown in the identification of a correlation between
CIN index and the grades of ovarian cancer subtypes [13].
Differences in a plethora of genomic features—including SNPs,
miRNAs, and gene copy number—can be visualized in the G-DOC
genome browser by selecting the chromosomal position or by using
a gene identifier. Several genomic features are available as data tiers
including phenotype information for mendelian disorders from Online
Mendelian Inheritance in Man (OMIM) and annotated SNPs from
dbSNP. The integration of information from OMIM, dbSNP, and
other sources helps to focus the investigator on genomic features that
are most likely to be functionally significant. Figure 4 shows copy num-
ber changes in a region of chromosome 12 from a pilot GI cancer study.
Clear differences in copy number changes can be seen between two
patients, a case that recurred and one that did not, viewed alongside
additional genomic features such as miRNAs and SNPs in the region.
Additional genomics features will be made available over time to supple-
ment this type of view.
My G-DOC
The G-DOC application allows for configurable security levels for
studies, and data can be made public (accessible to all users), restricted to
one or more collaboration groups, or available only to the data owner,
as dictated by the provider of the data. Previously published data are
always made public on loading within G-DOC. Collaboration groups
are limited groups of users, specified by the group manager, who can
share information among the members without exposing it to the en-
tire user population. The collaboration group manager has full control
Figure 2. Analysis of miRNA expression data in G-DOC: Analysis and visualization of differentially expressed miRNA in CRC samples versus
normal samples. Left, Heat map viewer showing clusters of coexpressed miRNAs. Middle, PCA scatter plot of tumor versus normal samples
based on expression data for 61 miRNA showing well-separated clusters of tumors and normal samples. Right, Venn diagram showing only
partial overlap between miRNAs differentially expressed in CRC stage II, III, and IV, with only eight miRNAs found to be in common for all
three sets of miRNAs. Far right, WNT signaling pathways with predicted targets of the eight miRNAs shown in gray. Analysis of predicted
targets has shown that this small group of miRNA regulates WNT signaling pathway known to be affected in colorectal cancer.
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over access to restricted data and to either approve or reject requests
for access. Collaboration groups allow users to share lists of patients,
genes, reporters, and analysis results in a secure, collaborative environ-
ment that fosters communication and team science. Additional ad-
ministrative functionality provided in G-DOC includes the ability to
manage user accounts and collaboration groups. The sum of these fea-
tures provides a workspace for groups that are either working on a data
analysis project or writing a grant as a team and can share analysis re-
sults, tools, and biomarker lists within their collaboration group—all
within a secure and managed environment.
G-DOC System Architecture
G-DOC is a Web-based application that provides users with a com-
prehensive set of analysis routines and visualizations for a rich user
experience. The application is written in Groovy & Grails, an open-
source development framework that runs on the Java Virtual Machine.
The jQuery JavaScript library is used to provide users with a cohesive
and interactive interface. For more complex data visualization, the
Adobe Flex framework provides users with integrated visualization
components that can handle complex charts and graphs and allow
these displays to interact with other functions within the application.
Besides the components developed in-house, G-DOC also incorporates
many third-party tools that provide data visualization capabilities. For
example, Java TreeView [14] is used to display heat maps, Cytoscape
[15] to display interaction networks, and JBrowse [16] provides a ge-
nome browser with multiple annotation tracks.
G-DOC is engineered and architected with future scalability as a
top priority. As such, the application and architecture were designed
to scale horizontally. The analysis server, Web application, and data-
base are each deployed on different virtual machines and sit behind a
load balancer. As the load on the application server increases, more
virtual machines can be added behind the F5 load balancer to keep
up with demand.
The G-DOC infrastructure consists of services and domain objects,
using the common open-source frameworks Spring and Hibernate
(an industry-standard object relational mapping technology). G-DOC
has a set of RESTful services that use JSON as a transfer medium, al-
lowing the different components to communicate with G-DOC in a
simple manner. A third-party tool, Lucene (cross-platform text search
engine), is used to index the database and provide users with a global
search capability.
The G-DOC analysis server provides an extensible framework for
analysis of study data. Analysis functionality includes the ability to
perform group comparisons (t test, Wilcoxon) and clustering (PCA
and hierarchical clustering). The analysis capability is implemented
Figure 3. PCA using 42 differentially expressed metabolite peaks
between relapse and nonrelapse cases with colorectal cancer; fold
change of 1.5 or higher; P ≤ .01.
Figure 4. Analysis of processed copy number data in conjunction with clinical information within the G-DOC genome browser. Patient tracks
can be dragged to the workspace to view genomic and clinical details. The “omics” tracks can be dragged in to see features that map to
various locations on the genome.
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using Java technologies including Java Messaging Service and the Java
Executor class library for multithreaded processing. The analysis in-
frastructure is hosted on a virtual machine with 16 GB of dedicated
memory. The analysis compute resources are easily scalable to a larger
memory or compute capacity as needed.
G-DOC provides functionality to save user-created lists of genes,
reporters, or patients for future reference and downstream analysis.
A robust set of list operations and visualizations is available including
the ability to perform intersections, unions, differences and to create
and export publication-quality Venn diagrams. User lists are persisted
in the database so that they can be referenced in future sessions and
shared with other users.
The G-DOC security infrastructure provides for secure login as well
as project- and role-based data access. User authorization in G-DOC
is implemented using the Spring security module which allows for user
provisioning. All communication between the G-DOC browser session
and the middle-tier is encrypted using the https protocol.
Methods
Currently, data collection within G-DOC is focused primarily on areas
of notable research and clinical strength at Georgetown University
and, as such, contains data from predominantly breast and GI cancers.
However, over time, this collection will broaden considerably and in
a manner consistent with feedback received by the user community.
Because facilitating translational research is the overarching goal of
G-DOC, high-throughput “omics” data sets that have corresponding
clinical information from human subjects are preferentially entered
and will be so for the foreseeable future, although a few “tumor-versus-
normal” data sets are also present. A list describing the current data
collection, including types of data available, is available at all times on
the G-DOC Web portal front page.
The data collection of G-DOC is composed of two divergent sets—
public data that are available to all registrants and private data that are
supplied by, and accessible to, individual investigators and their collab-
oration groups. Public data sets are typically obtained from repositories
such as National Center for Biotechnology Information Gene Expres-
sion Omnibus [17] and EBI Array Express [18], whereas private data
sets are uploaded to a secure SSH file transfer protocol server for han-
dling by an analysis team. A set of standard operating procedures are
followed before data are accepted from collaborators to ensure that
all data are deidentified in accordance with Health Insurance Portabil-
ity and Accountability Act regulations; G-DOC neither stores nor dis-
tributes patient identifiable information.
Once data sets have been obtained, either from public repositories
or through private transfer, the “omics” data are preprocessed and
the clinical information is mapped to the existing data structures as a
precursor to loading within the G-DOC database. Uniform prepro-
cessing and normalization ensures maximum comparability between
analyses and studies and ensures that the data within G-DOC provides
the greatest scientific leverage to the user community. Specific pipe-
lines have been established, tailored to each data type, and emphasize
standard and uniform data preprocessing to ensure utmost quality, a
key factor in minimizing noise and false-positives. All data and accom-
panying query features are subjected to rigorous QC procedures before
being made available in the production environment.
Several files are created describing the clinical attributes with respect
to their type and vocabulary, outlining specifics such as format and
range. Special files are also created for each data type in the study de-
scribing the mapping between the clinical and corresponding high-
throughput data samples (after preprocessing). The summary, study
characteristics, and contact information are captured in a separate
format. This set of files is stored in a version-controlled data repository
using a consistent naming convention to describe each study: Cancer-
abbreviation_Principal-investigator_Publication-year_iteration (e.g.,
BRC_WANG_2005_01 for Wang et al., 2005; PMID: 15721472).
Special attention is paid to capturing and persisting the disease out-
comes and end point information because these serve to enable a series
of value-added features of G-DOC (e.g., Quick Start, interactive Kaplan-
Meier plots) that better support translational research activities. Studies
are stored within G-DOC in an Oracle 11g relational database, which
consists of 44 common tables. For each new study loaded, a separate
schema is created consisting of a set of 12 study-specific tables. All pro-
cessed data files pertaining to a particular study are loaded separately
onto a computation-centric server designed to handle high-throughput
data analysis. Analyses that are run against study data reference their re-
spective processed (binary) file to complete a variety of statistical routines.
All analysis routines that run in the G-DOC environment are written
in the R language to ensure modularity, ease of deployment, and high
performance on the computational server nodes that provide analytic
services to the user community. A high-level overview of data, annota-
tions, and analysis available in G-DOC are illustrated in Figure 5. The
processing that occurs before data entry is detailed below for the four
major types of “omics” data presently available in G-DOC (mRNA,
miRNA, metabolomics, copy number). Whereas G-DOC does not
currently contain any high-throughput sequencing information (exon
sequencing, CHIP-Seq, RNA-Seq), these and other related data types
will be supported in a future version of G-DOC.
mRNA Expression Data
Much of the data currently within G-DOC are mRNA expression
data produced by array hybridization experiments, including both two-
channel ratio data and single-channel intensity data. These are retrieved
in a raw .CEL file format (Affymetrix, Santa Clara, CA) or a tab-delimited
text file format (Agilent, Santa Clara, CA), as appropriate, from the public
archives or from the laboratory that generated these data. Other formats
are being considered for future versions of the tool. Preprocessing of
microarray data primarily involves normalization with either Robust
Multichip Average [19] or Quantile Normalization [20] followed by log
transformation of the data. More information on these standard normal-
ization strategies is available at http://www.bioconductor.org. Significant
postprocessing effort is expended to ensure data quality and retention of
the biologic information provided. Transcripts (mRNAs) are mapped on
the genome in the JBrowse genome browser interface based on Build 36
of the National Center for Biotechnology Information genome.
miRNA Expression Data
MicroRNA is a subject of growing interest for the clinical, transla-
tional, and basic science cancer communities, and G-DOC supports
this data type. A data preprocessing pipeline was developed for miRNA
expression data that supports the major highthroughput platform
formats: oligonucleotide microarrays (Agilent and Illumina) and real-
time quantitative polymerase chain reaction arrays (Life Technologies,
Inc, Carlsbad, CA). Microarray-generated data sets are processed from
raw data files using global median normalization [21,22], whereas real-
time quantitative polymerase chain reaction data are processed using
comparative CT method [23] and normalized to the average signal of
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endogenous controls [24]. These miRNA reporter IDs are mapped to
mature miRNA accession numbers in the miRBase [25] and hyper-
linked to online public databases (miRBase, Entrez, and iHOP), pro-
viding instant access to comprehensive miRNA genomic and deep
sequencing information as well as predicted targets. miRNAs are also
mapped on the genome using the JBrowse genome browser interface.
Metabolomics Data
Metabolomics is one of the newer “omics” sciences and aims to study
global profiles of small-molecule metabolites within a biologic system
under a given set of conditions. Typically, these experiments are per-
formed on biofluids such as urine, saliva, or blood plasma, but isolated
cells and tissues may also be used. The G-DOCmetabolomics data col-
lection is exclusively mass spectrometric data, but the data structures
are sufficiently generic to support other typical metabolomics data types
(e.g., nuclear magnetic resonance, gas chromatography) in the future.
For mass spectrometry data, a number of vendor-specific software pro-
grams, tailored to the specifics of the acquisition hardware, are available
to convert spectral data into universal data exchange formats such as
network common data form (http://www.unidata.ucar.edu/software/
netcdf/), mzXML [26], and mzDATA. To ensure maximal future flexi-
bility, the G-DOC preprocessing pipeline is built to work with all these
formats. The metabolomics data contained within G-DOC were
processed into a data matrix format with samples as columns and
peaks/metabolites as rows and were normalized row-wise or column-
wise in a sequential manner to minimize systematic variance and im-
prove the performance for downstream statistical analysis.
DNA Copy Number Data
Considerable attention has been paid to understanding the gross
chromosomal modification events that are common within many
types of cancer. Although the technologies used have progressed (e.g.,
SNP and cDNA array hybridization replacing loss of heterozygosity),
significant interest remains in identifying the aberrations that occur
within the development and progression of neoplasias. To ensure that
G-DOC can enable investigators to best use this type of data, a data
processing pipeline was developed using R (http://www.r-project.org/)
for analysis and visualization of DNA copy number data obtained
from a variety of platforms. Raw data from the most common plat-
forms, Affymetrix SNPchip and Agilent CGH arrays, are preprocessed
using D-Chip [27] to extract a signal for individual probes. Piecewise
constant segments of copy number profiles are estimated based on
the fused margin regression method [28]. Probe-level data are further
processed to calculate copy number segments and CIN index [13], one
Figure 5. Overview of data and analysis features in G-DOC. Data (public or private) are uniformly processed through standard bioinformatics
pipelines and made available to various analysis tools through a clinician- and researcher-friendly Web interface.
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of the value-added analyses that come pregenerated within G-DOC.
Segment data are used for calculation of CIN index at the level of whole
chromosomes and individual cytobands [13].
Results
A G-DOC Storyboard
To exemplify the powerful integration that G-DOC provides to
analyze large molecular and clinical data sets, we demonstrate here
how a user could generate and validate a scientific hypothesis using this
system. In this example, we will test the hypothesis that there are re-
producible gene expression differences that can be identified between
recurrent and nonrecurrent estrogen receptor–positive (ER+) tumors in
tamoxifen-treated node-negative breast tumors. The G-DOCWeb tool
permits us to perform this analysis quickly and easily using nothing
but a collection of publicly available data sets obtained from the bio-
medical literature. This exercise will include identification of a molec-
ular profile in one public study [29] and its validation in another [30].
1. Can we identify, within each data set, two tamoxifen-only–
treated patient cohorts that are ER+, irrespective of nodal status,
have uniform gene expression array data available in G-DOC,
but differ only by whether they recurred within 5 years or did
not? Using G-DOC, users can specify these criteria in a clinical
data search form to create two (or more) lists of patients that
meet these criteria (Figure 6). These two cohorts frame the
question posed above; other clinical considerations that are part
of the published data could also have been added to the strati-
fication. Upon saving, both sets of patient lists will be imme-
diately available in the “Saved Lists” section, and they can be
revisited at any time.
2. Are there clear molecular signatures that are distinct between
these two patient cohorts (recurrent; nonrecurrent)? Selecting
the cohorts to compare, the optimal statistical parameters to
use, and the experimental data set to be used are all needed to
fully configure the analysis that will be run (Figure 7A). Output
of this analysis is a list of annotated probes, filtered by the input
specifications, which differentiate between the patient cohorts
in the first (training) data set (Figure 7B); output comes in a
sortable table. Visualization through an expression heat map
generated by a modified Java TreeView [14] is supported, per-
mitting the investigator to easily view the results of his/her search
to ensure scientific validity of the separation and, if desired, se-
lect a subset of the probes to examine in more detail. The saved
list of probes identified in this group comparison analysis can
be used as the input variables in a PCA classification test [31].
PCA can be used to determine whether the data are line-
arly separable in the two-dimensional data space defined by the
top two principal components. The list of reporters generated
can also be used to probe the validation data set in Sotiriou et al.
[30] to explore reproducibility of the results from the train-
ing data set.
3. Explore the reporter list to identify genes that are transcription
factors and that potentially regulate the effects of tamoxifen treat-
ment. After identification of a probe list in G-DOC that shows
efficacy in separating tamoxifen-treated, ER+, node-negative
breast cancer patients who had recurrence from those who did
not, it is expected that some additional examination of these
genes would be undertaken to probe the biologic mechanism
Figure 6. The results from a clinical search are shown in a sortable table in G-DOC. A variety of options for saving and exporting these
results are supported.
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and validity of any new discovery. For example, the top-scoring
gene on the group comparison of Loi et al. [29] (Figure 7B),
MYBL1 is a known regulator of transcription [32].
4. Does up-regulation of MYBL1 impact survival in these patient
cohorts? From the reporter list, this gene can be selected to gen-
erate a Kaplan-Meier [33] plot in G-DOC based on disease-free
survival for these patients. As can be seen in Figure 8, there is a
statistically significant (P < .05; log-rank test) separation between
samples with 1.4-fold upregulated versus downregulatedMYBL1.
5. In the face of this information, can even more detailed analysis
of the role of this gene in cancer biology be undertaken through
links to external data resources? The entire list of genes iden-
tified in this analysis, or similar searches, can be visualized as a
whole using the Cytoscape viewer [15] and integrated within G-
DOC to retrieve all the Cancer Gene Index data (https://wiki.
nci.nih.gov/display/ICR/Cancer+Gene+Index+End+User+
Documentation) available for the set of genes, including their
degree of interconnectedness. Within the flexible and powerful
Cytoscape viewer, it is possible to explore groups of genes and
biologic concepts or, conversely, to focus in detail on one gene of
interest, such as MYBL1 (Figure 9). Users can access a number
of public annotation databases through G-DOC including the
STRING database [34]. The data set in STRING shows affilia-
tions between this top-scoring gene (MYBL1) and some others
of note, including BCL2, a known regulator of apoptosis, whose
over expression is caused byMYBL1, which is in turn negatively
regulated by nucleolin (not shown). Entrez, GeneCards [35],
and the Protein Information Resource [36] are a small subset
of resources that can be easily and directly accessed from this view
(Figure 9).
6. Finally, is it possible to gain a more complete understanding
of this gene of interest by exploring its genomic context using
the integrated genome browser within G-DOC? In this case,
we wish to understand not only the structure of the gene but
also the features of adjacent genome regions. A number of these
features are available as existing JBrowse [16] (see also Figure 4)
data tiers, including OMIM [37] data and SNPs from dbSNP
[38]. In this case, we wish to take the analysis further by exam-
ining the copy number changes at the MYBL1 locus for cancer
patients. Users can explore the chromosomal region around this
gene of interest, which is noted to be a region of chromosomal
loss for patients in a third study [39], which has copy number
Figure 7. A. It is possible to very specifically configure analyses within G-DOC to generate results to enable scientific discovery or
validation of hypotheses. Both basic (e.g., fold change cutoff) and advanced (e.g., multiple hypothesis correction) options are available.
B. Results of an analysis in G-DOC are displayed clearly, and a variety of options for saving or exporting are supported within the tool.
This is the results page from the comparison of the two cohorts identified from the study of Loi et al. [29].
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alteration data already processed and loaded into G-DOC. An-
other possibility would be to use the CIN index [13] to view the
degree of instability between cohorts of patients at the
chromosomal or cytoband level, shown here for two cohorts
(in this case, metastatic and nonmetastatic, not the clinical pa-
rameters used in the study of Loi et al. [29]) from the data set of
Sircoulomb et al. [39], most quickly accessed using the Quick
Start feature. In this case, MYBL1, which resides on 6q13.1, is
in a region that does not show a marked difference of instability
between metastatic and nonmetastatic patients from the study
of Sircoulomb et al. [39].
The storyboard presented here shows that G-DOC can effectively
be used to develop and test a scientific hypothesis entirely in silico,
allowing more resources to be spent on further downstream validation
or hypothesis refinement in the laboratory or clinic. The G-DOCWeb
portal was designed to provide powerful integrated bioinformatics
capabilities to the user community, with the hope of advancing bio-
medical and translational research in oncology.
Discussion
G-DOC and Translational Research
The G-DOC portal was developed as a resource for basic and trans-
lational research, and it can greatly speed the process of discovery and
validation by providing a powerful platform that supports a wide variety
of data analyses and diverse exploration of results. By integrating a
Figure 8. G-DOC supports the generation of Kaplan-Meier plots to help visualize the effect of gene overexpression on patient survival.
Note here that the effect of strong overexpression (red) versus strong underexpression (blue) of MYBL1, as seen in the data set of Loi
et al. [29], shows a statistically significant impact on patient survival. Differences in survival between either of these groups and patients
with intermediate expression (yellow line) are not statistically significant.
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variety of clinical and “omics” data types, researchers can use the re-
sources and capabilities of G-DOC to more effectively pursue their
translational research agenda. As an illustration of the value of systems
approaches used in G-DOC, the predictive power and robustness of
biomarkers can be significantly increased by integrating transcriptome
profiles with interactome data to reveal more relevant functional sub-
network modules [40]. Clearly, transcriptome and proteome analyses
of collections of cancer samples combined with functional annotation
and modeling of perturbations in molecular pathways and networks
have revealed useful biomarkers for the classification and diagnosis of
cancer subtypes, the prognosis of patient outcomes, the prediction of
treatment responses, and the identification of putative targets for drug
discovery [41,42]. G-DOC not only provides a platform to interro-
gate individual data types but also allows for combination of data
from various platforms, such as transciptomics and metabolomics,
helping to identify more robust signatures of disease. By supporting
easy access to valuable outside resources such as pathway networks
and protein-protein interactions, it is hoped that G-DOC can be used
as a central hub for discovery and hypothesis generation, as well
as validation, in cancer research. Secure exchange of data and anal-
yses within this multi-institutional project team will facilitate closer
interactions among researchers and rapid exchange and testing of
working hypotheses.
G-DOC and Systems Medicine
More than conventional medicine, systems medicine attracts in-
creasing research interest in the cancer community because it offers a
true paradigm shift that may efficiently lead to large, rather than in-
cremental, advances in clinical practice [43]. Importantly, preliminary
data show that inexpensive high-throughput “omics” analyses of blood
and urine can predict clinical course as well as or better than traditional
genomic analyses of tissues (unpublished observations). Integrative and
systems medicine platforms such as G-DOC are critical to facilitating
the eventual use of “omics” data to drive innovative advances in per-
sonalized clinical care and improve the quality and quantity of life
for cancer patients. As part of the exploration of this long-term trend,
global “omics” profiling studies from a variety of high-throughput tech-
nologies are providing comprehensive surveys of molecular changes that
are involved in the occurrence and recurrence of many cancers [44].
Combined with an expected concurrent increase in the availability of
clinical, pathology, and outcome information from hospital medical
center electronic health records systems, data from omics studies are
expected to provide an unprecedented opportunity for the advancement
of clinical practice. In the near future, physicians will be able to integrate
and explore these data sets to understand the heterogeneity of cancers
and more efficiently identify diagnostic and prognostic markers. As this
paradigm shift becomes more accepted, demand from physician re-
searchers to navigate seamlessly between the phenotypic and genotypic
characteristics of a patient, to better tailor their treatment plans, will
likewise markedly increase.
Finally, as these large data sets become available for research and to
inform clinical practice, it is anticipated that an even bigger challenge
will arise—the desire to explore and understand how the cancer genome
functions as a complex biologic system in individual patients in relation-
ship to environment, lifestyle, and genetic heritability. New tools will
be needed to support these requirements, although many are anticipated
to be addressed in future versions of G-DOC.
G-DOC and the Clinical Practice of Systems Medicine
While systems biology will provide the foundation for a practice of
systems medicine in the future that will be predictive, personalized,
preventive, and participatory [45], it needs to be optimally integrated
with health care management systems, imaging centers, and biobanks,
as well as subjected to updated ethical regulations, review, and over-
sight to produce an effective regimen [46]. This will require dedicated
efforts of interdisciplinary experts and special attention to clinical prac-
tice and education. Platforms such as G-DOC are one part of the sys-
tems medicine puzzle to extract knowledge from various types of data
and present them to multidisciplinary teams to provide a medium of
communication among them.
G-DOC—Comparison with Other Resources
G-DOC was designed and engineered to be a unique resource for
translational cancer research that fills critical gaps in the existing re-
search space. It integrates clinical, transcriptomic, metabolomic, and
systems-level analysis into a single platform. While Oncomine [47]
provides biologist-friendly data mining, the focus of this resource is
primarily on cancer transcriptome data, and unlike G-DOC, many
of the cancer data sets and features of Oncomine require an annual sub-
scription fee, rather than being freely provided. ArrayExpress [18], the
StanfordMicroarray Database [48], and the Gene Expression Omnibus
[17] repositories have proven to be highly valuable in standardizing
and distributing cancer microarray data, but these resources do not well
support data analysis, data mining, or systems-level analysis. They also
focus primarily on microarray data rather than the range of nonarray
“omics” data types, such as mass spectrometry metabolomics data,
present in G-DOC. In summary, G-DOC is a unique resource for
cancer data and integrative analysis and is currently available freely to
the cancer research community.
Future Advances and Needs
The long-term vision for G-DOC involves establishing a robust and
comprehensive systems medicine platform that can directly impact
health care delivery in the clinical setting by providing more effective
clinical decision support. An additional challenge for the future will
Figure 9. Many links from G-DOC to external resources are sup-
ported, enabling investigators to use G-DOC as a central resource
for their scientific explorations of public or private data sets.
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be to use decision support tools to improve quality of life even when im-
proved health outcomes are not possible, such as in palliative care [49]. In
its current form, G-DOC already provides the means by which an array
of existing and emerging “omics” data can be marshaled to improve the
outcome for individual patients, and subsequent integration with elec-
tronic health records is prioritized for implementation in G-DOC based
on its expected impact on both clinical research and clinical practice.
We anticipate that G-DOC and tools like it will soon have a direct
impact on human health, although the pace of adoption and utilization
within the clinical community is, and will likely remain, the major rate-
limiting factor. To effectively use these tools in clinical care, a new type
of physician, one with a grasp of modern computational sciences,
“omics” technologies and a systems approach to medicine, is a critical
component. We expect these subjects, and the tools that underlie them,
to enter the medical curriculum to better enable future physicians to
effectively use systems based approaches in the clinic.
Availability
G-DOC is freely available to all users at https://gdoc.georgetown.
edu. Registration and acceptance of terms of use are required before
first login.
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